Clinical Trials
5 trialsNCT04539366 2026-05-13
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial
National Cancer Institute (NCI)
Phase 1 Suspended
NCT07422363 2026-05-13
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT06964737 2026-05-08
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT03598244 2025-04-20
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02700230 2024-09-27
Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Mayo Clinic
Phase 1 Completed